Retention Test Homburg To Monitor the Adhesive Properties of von Willebrand Factor after Substitution or Desmopressin Therapy

ABSTRACT

To diagnose von Willebrand disease (vWD) and to monitor drug efficacy, several tests have been established that are not, however, focused on the platelet adhesion properties of von Willebrand factor (vWF). The new platelet retention test Homburg (RTH) is characterized by a nonthrombogenic filter that retains platelets from blood when it is pressed through this filter. It was the aim of this study to examine the capability of this test to monitor the adhesive properties of vWF after its substitution in vWD or its release by desmopressin infusion.

The RTH demonstrated a striking sensitivity for vWF after its release from endogenous storage sites or its supplementation in vivo as well as in vitro, whereas it did not detect an inhibition of platelet aggregability due to aspirin.

Desmopressin infusions led to an immediate and highly significant increase of RTH platelet retention, followed by a gradual decline to initial values during the next 4 hours. The transfusion of a vWF concentrate also resulted in RTH data that demonstrated different kinetics than established parameters such as vWF:antigen, vWF:RiCoF, or the PFA-100 in vitro bleeding analysis. Additional in vitro experiments confirmed the correlation of RTH values with vWF concentrations.

In conclusion, the RTH may be efficient to complement presently used measures to monitor vWD therapy with desmopressin or vWF concentrates.

KEYWORDS

Platelets - platelet adhesion - von Willebrand factor - von Willebrand disease - desmopressin

REFERENCES

• 1 Furlan M. von Willebrand factor: molecular size and functional activity.  Ann Hematol. 1996;  72 341-348
• 2 de Groot P G. The role of von Willebrand factor in platelet function.  Semin Thromb Hemost. 2002;  28 133-138
• 3 Scott J P, Montgomery R R. Therapy of von Willebrand disease.  Semin Thromb Hemost. 1993;  19 37-47
• 4 Ruggeri Z M, Dent J W, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood.  Blood. 1999;  94 172-178
• 5 Ruggeri Z M. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation.  Best Pract Res Clin Haematol. 2001;  14 257-279
• 6 Siekmann J, Turecek P L, Schwartz H P. The determination of von Willebrand factor activity by collagen binding assay.  Haemophilia. 1998;  4 15-24
• 7 Mannucci P M. Treatment of von Willebrand disease.  Thromb Haemost. 2001;  86 149-153
• 8 Lethagen S, Berntorp E, Nilsson I M. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III.  Ann Hematol. 1992;  65 253-259
• 9 Mannucci P M, Tenconi P M, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial.  Blood. 1992;  79 3130-3137
• 10 Lillicrap D, Poon M C, Walker I, Xie F, Schwartz B A. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: Ristocetin cofactor unit dosing in patients with von Willebrand disease.  Thromb Haemost. 2002;  87 224-230
• 11 Mammen E F, Comp P C, Gosselin R et al.. PFA-100 system: a new method for assessment of platelet dysfunction.  Semin Thromb Hemost. 1998;  24 195-202
• 12 Schumann A, Bucha E, Nowa G. Platelet adhesion assay PADA).  Semin Thromb Hemost. 2005;  31 476-481
• 13 Hellem A J. Platelet adhesiveness in von Willebrand's disease. A study with a new modification of the glass bead filter method.  Scand J Haematol. 1970;  7 374-382
• 14 Salzman E W. Measurement of platelet adhesiveness: a simple in vitro technique demonstrating an abnormality in von Willebrand's disease.  J Lab Clin Med. 1963;  62 724-735
• 15 Niessner H. Messung der Plattchenadhäsivität mit einer modifizierten Form der Hellem II-Methodik unter besonderer Berücksichtigung des von Willebrand-Jürgens-Syndroms [Measurement of platelet adhesiveness using a modified form of the Hellem II method with special reference to Willebrand-Jurgens syndrome].  Thromb Diath Haemorrh. 1972;  27 434-451
• 16 Kenet G, Lubetsky A, Shenkman B et al.. Cone and platelet analyser (CPA): a new test for the prediction of bleeding among thrombocytopenic patients.  Br J Haematol. 1998;  101 255-259
• 17 Sakariassen K S, Aarts P A, de Groot P G, Houdijk W P, Sixma J J. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components.  J Lab Clin Med. 1983;  102 522-535
• 18 Reininger A J, Agneskirchner J, Bode P A, Spannagl M, Wurzinger L J. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor.  Thromb Haemost. 2000;  83 217-223
• 19 Wieding J U, Köstering H, Peine S, Wermes C, Mestres P, Wenzel E. Plättchen-Retentionstest Homburg: Drug monitoring der Plättchenadhäsivität des von Willebrandfaktors [Platelet retention test Homburg (RTH) and drug monitoring of platelet adhesive properties of von Willebrand factor].  Haemostaseologie. 2004;  24 217-220
• 20 Merrill E W, Salzman E W, Wan S et al.. Platelet-compatible hydrophilic segmented polyurethanes from polyethylene glycols and cyclohexane diisocyanate.  Trans Am Soc Artif Intern Organs. 1982;  28 482-487